“I am encouraged by the safety profile and initial signals of anti-viral activity of IMC-M113V in the Phase 1/2 trial. It is uncommon to be able to interrupt ART for 12 weeks or longer, with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback